Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Biotechnology
Pharmaceuticals, Biotechnology & Life Sciences
Common Stock
β +0.994
Website
Attributes
Seasonality
Filters